

November 10, 2025

Company	Japan Investment Adviser Co., Ltd.
Representative	President & CEO Naoto Shiraiwa (TSE Prime Market, Stock Code: 7172)
Contact	Board of Director Takeshi Sugimoto
TEL.	81-3-6550-9307

Notice of Regarding New Investment for the Private Equity Investment Business ~ThinkCyte K.K.~

Japan Investment Adviser (JIA) Group hereby announce that a fund managed by the JIA Group has acquired the shares of ThinkCyte K.K. (hereinafter referred to as “ThinkCyte”) as a new investment company. The JIA Group has realized the IPOs of ten companies and M&A exits for two companies so far. (※)

(※ Reference) Investee companies of the JIA Group: <https://www.jia-ltd.com/en/business/privateequity/>

1. Purpose of the investment

ThinkCyte, a start-up founded in 2016, dedicated to advancing life science and healthcare and driving innovation in these fields. ThinkCute's work is based on cutting-edge technologies developed at the University of Tokyo and the University of Osaka.

ThinkCyte provides researchers with a means to rapidly measure and utilize high-resolution data on cell morphology and extract critical insights, through the development of VisionSort™ (*1), its cell analysis and sorting equipment that integrates advanced technologies in optics, microfluidics, and artificial intelligence (AI).

VisionSort™ is equipped with ThinkCyte's world-first "Ghost Cytometry" technology, which allows for AI-based cell classification and sorting. This offers an unprecedented methodology for various R&D scenarios involving cells. Through the deployment of VisionSort™, ThinkCyte will contribute to the progress of cell therapy, drug development, and disease profiling (*2), fields that depend on precise cell analysis and isolation.

The JIA Group has decided to acquire the shares of ThinkCyte to support their further business growth. We aim to support their mission to realize new regenerative and cellular medicines, medical diagnostics, and drug development through the creation of innovative cell analysis technologies.

(*1) This is an experimental instrument primarily used in life science and healthcare research. Its function is to identify (analyze), select, and isolate specific cell types from heterogeneous samples, such as those derived from blood or tissues.

(*2) The detailed and comprehensive analysis of a patient's biological materials (including cells, tissues, and body fluids like blood) to holistically understand the characteristics and mechanisms of each disease.

2. Overview of ThinkCyte

(1) Company Name	ThinkCyte K.K.
(2) Address	7-3-1 Hongo, Bunkyo-ku, Tokyo
(3) Name and title of representative	Chief Executive Officer, Co-founder Waichiro Katsuda
(4) Description of Business	R&D and Sales of scientific instrumentation for physical and chemical applications.
(5) Establishment	February 1, 2016
(6) Homepage	https://thinkcyte.com/

3. Future outlook

The impact of this matter on the JIA Group's business performance is minor at this moment.

Inquiries:

PR/IR group

TEL: 81-3-6550-9307

End